2060571-02-8

Basic information

• Product Name: GDC-0077
• Synonyms: GDC-0077;RG 6114;RO 7113755
• CAS NO: 2060571-02-8
• Molecular Formula: C18H19F2N5O4
• Molecular Weight: 407.3713664
• Mol File: 2060571-02-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: GDC-0077(CAS DataBase Reference)
• NIST Chemistry Reference: GDC-0077(2060571-02-8)
• EPA Substance Registry System: GDC-0077(2060571-02-8)

Safety Data

• Hazardous Substances Data: 2060571-02-8(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
GDC-0077 is used as a targeted therapy for various cancer types, including breast cancer and other solid tumors with PIK3CA mutations. It works by inhibiting the PI3K pathway, which is crucial for cancer cell growth and survival, leading to the suppression of tumor progression.
Used in Clinical Trials:
GDC-0077 is currently being evaluated in clinical trials to assess its potential as a targeted therapy for various cancer types. Early results have shown encouraging efficacy and a favorable safety profile, indicating its potential as a valuable treatment option for cancer patients.
Used in Drug Development:
As a potent and selective PI3K inhibitor, GDC-0077 serves as a valuable compound in the development of new cancer therapies. Its ability to target a specific signaling pathway involved in cancer cell growth and survival makes it a promising candidate for further research and development in the field of oncology.

Upstream product

• 1282516-67-9 9-bromo-5,6-dihydrobenzo[f ]imidazo[1,2-d][1,4]oxazepine 
• 1282516-68-0 9-bromo-2,3-diiodo-5,6-dihydrobenzo[f ]imidazo[1,2-d][1,4]oxazepine 
• 1282516-69-1 9-bromo-2-iodo-5,6-dihydrobenzo[f ]imidazo[1,2-d][1,4]oxazepine 
• 591-20-8 3-Bromophenol 
• 56-41-7 L-alanin 
• 22532-62-3 4-bromosalicylaldehyde 
• 1282516-66-8 5-bromo-2-(1H-imidazol-2-yl)phenol 

Relevant articles and documents

Synthesis of PI3K inhibitor GDC-0077 via a stereocontrolled N-arylation of α-amino acids

An efficient synthesis of PI3K inhibitor GDC-0077, featuring two consecutive Cu-catalyzed C–N coupling reactions, is reported. The described synthetic route involves a chemoselective Ullmann-type coupling of a chiral difluoromethyl-substituted oxazolidinone, a Cu-catalyzed N-arylation of L-alanine with high stereochemical integrity, and a high-yielding final amide bond formation step to produce GDC-0077 in >99.5 area % HPLC purity.

PROCESS FOR THE PREPARATION OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO) PROPANAMIDE

Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound 18, having the structure (I).

POLYMORPHS AND SOLID FORMS OF (S)-2-((2-((S)-4-(DIFLUOROMETHYL)-2-OXOOXAZOLIDIN-3-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPIN-9-YL)AMINO)PROPANAMIDE, AND METHODS OF PRODUCTION

The present invention relates to crystalline polymorph forms of (5)-2-((2-((5)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[?]imidazo[ 1,2-J] [ 1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.

BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE

Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide- 3 kinase (PI3K) modulation activity or function having the Formula (I) structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.